Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G

Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G

Blog Article

Human respiratory syncytial virus (RSV) poses a significant human health threat, particularly to infants and the elderly.While efficacious vaccines based on the F protein have recently received market authorization, uncertainties remain regarding the future need for vaccine updates to counteract potential viral drift.The attachment protein G has long been ignored as a vaccine target due to perceived non-essentiality and ineffective neutralization on immortalized cells.Here, we show strong G-based BURDOCK ROOT neutralization in fully differentiated human airway epithelial cell (hAEC) cultures that is comparable to F-based neutralization.Next, we designed an RSV vaccine component based on the central conserved domain (CCD) of G fused to self-assembling lumazine synthase Glass Dripper (LS) nanoparticles from the thermophile Aquifex aeolicus as a multivalent antigen presentation scaffold.

These nanoparticles, characterized by high particle expression and assembly through the introduction of N-linked glycans, showed exceptional thermal and storage stability and elicited potent RSV neutralizing antibodies in a mouse model.In conclusion, our results emphasize the pivotal role of RSV G in the viral lifecycle and culminate in a promising next-generation RSV vaccine candidate characterized by excellent manufacturability and immunogenic properties.This candidate could function independently or synergistically with current F-based vaccines.